(Q34583857)

3 August 2017

1 reference

title

The ErbB receptor family: a therapeutic target for cancer (English)

1 reference

3 August 2017

Johann S de Bono

1

1 reference

PubMed ID

11927283

3 August 2017

Eric K Rowinsky

series ordinal

2

1 reference

3 August 2017

1 January 2002

1 reference

Trends in Molecular Medicine

3 August 2017

1 reference

3 August 2017

8

1 reference

3 August 2017

4 Suppl

1 reference

3 August 2017

S19-26

1 reference

Cell signaling by receptor tyrosine kinases

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Receptor tyrosine kinases: specific outcomes from general signals

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Mechanism of action of trastuzumab and scientific update

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902306-7

7 January 2021

10.1016/S1471-4914(02)02306-7

Identifiers

DOI

1 reference

release_bz2wvje5izhr5mv32odxh463u4

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bz2wvje5izhr5mv32odxh463u4

24 November 2022

mapped directly with Wikidata item

PubMed ID

11927283

1 reference

PubMed ID

11927283